Carcinoid Heart Disease: A Retrospective Study and a Multidisciplinary Proposal of a New Algorithm

#2703

Introduction: Development of carcinoid heart disease (CHD) is the major negative prognostic factor in patients with the carcinoid syndrome. The only effective treatment is valve replacement. However, the selection of candidates and determination of optimal timing remain unclear. Considerable variability in local treatment strategies exist

Aim(s): Carcinoid syndrome (CSy) is a constellation of symptoms that may commonly present in patients with well differentiated neuroendocrine tumors (NETs), with somatostatin analogs (SSAs) being the first-line option for symptom management.

Materials and methods: In this single-centre study, we retrospectively analysed the diagnostic process and outcome of all patients CHD who underwent sandostatin analogue 120 mg between 2016 and 2019 with or without chemotherapy. We report a series of 12 patients followed in the medical oncology departement we propose a new CHD manegement algorithm

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bengueddach A, Kehili H, Kaid M, Bereksi Reguig F, Bousahba A,

Keywords: carcinoid heart disease, somatostatin analogue, neuroendocrine tumors,